Search

2023 SEP 9 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on pulmonary embolism. According to news reporting from [...]

2018 MAY 26 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Data detailed on Cardiovascular Diseases and Conditions - Deep Vein Thrombosis have [...]

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.amjmed.2008.05.045 Byline: Raza Alikhan (a), Alex C. Spyropoulos (b) Keywords: Chronic obstructive pulmonary disease; Deep vein thrombosis; Epidemiology; Heart failure; Infection; Pulmonary embolism; Thromboprophylaxis; Venous thromboembolism Abstract: Venous thromboembolic complications -- deep vein thrombosis and pulmonary embolism -- occur in a significant proportion of hospitalized medical patients. The incidence in acutely ill medical patients is 10%-40%, equivalent to that seen in general surgical patients. Prophylaxis is effective and well tolerated, yet remains under-prescribed in medical wards. Current recommendations for prophylaxis are generalized and do not specifically address many patient groups. Data on the prevalence in patients with chronic obstructive pulmonary disease, heart failure, and infectious diseases are limited. However, studies on large numbers of hospitalized patients with these admission diagnoses have provided important information on incidence, and the efficacy of thromboprophylaxis. This review summarizes current knowledge of the epidemiology of venous thromboembolism in patients with chronic obstructive pulmonary disease, heart failure, and infectious diseases, and highlights the benefits of, and needs for, appropriate prophylaxis in these groups. Increased awareness of the prevalence of thrombosis in the major subgroups of medical inpatients should improve the prescribing of prophylaxis and prevent potentially avoidable and costly complications. Author Affiliation: (a) Department of Haematology, John Radcliffe Hospital, Oxford, UK (b) Clinical Thrombosis Center, Lovelace Medical Center, Albuquerque, NM

2017 AUG 12 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Researchers detail new data in Lung Diseases and Conditions - Pulmonary Embolism. [...]

2017 JUL 1 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Fresh data on Cardiovascular Diseases and Conditions - Venous Thromboembolism are presented [...]

INTRODUCTION Deep venous thrombosis (DVT) and pulmonary embolus (PE) are major risk factors for patients undergoing surgical or other invasive procedures, and thromboprophylaxis should be considered for all these patients. [...]

* EVERY YEAR, THOUSANDS OF PATIENTS develop deep vein thrombosis (DVT) after undergoing surgery. Deep vein thromboses that result in pulmonary embolisms (PEs) are believed to be one of the most frequently occurring, preventable killers of hospitalized patients. * STRATEGIES FOR PREVENTING a patient from developing DVT include implementing chemical or mechanical prophylaxis or a combination of the two. * BY INSTITUTING a DVT-assessment program, implementing mechanical DVT prophylaxis, and educating nurses and patients, the incidence of DVTs in orthopedic patients can be reduced, leading to fewer deaths from PEs., Deep vein thrombosis (DVT) and pulmonary embolism (PE) affect between 200,000 and 600,000 Americans each year. Of those patients who develop a PE, 60,000 to 200,000 will die. (1) Pulmonary [...]

Background: The optimal duration of oral anticoagulant treatment after a first episode of pulmonary embolism remains uncertain. Objective: To evaluate the long-term clinical benefit of extending a 3-month course of oral anticoagulant therapy to 6 months (pulmonary embolism associated with temporary risk factors) or to 1 year (idiopathic pulmonary embolism) in patients with a first episode of pulmonary embolism. Design: Multicenter randomized study with independent, blinded assessment of the outcome events. Setting: 19 Italian hospitals. Patients: 326 patients who had had 3 months of oral anticoagulant therapy without experiencing recurrence or bleeding. Measurements: The primary study outcome was recurrence of symptomatic, objectively confirmed venous thromboembolism. Results: Among 165 patients assigned to extended anticoagulant therapy, 15 patients (9%) had a recurrence of venous thromboembolism (3.1% per patient-year; average follow-up, 34.9 months), as compared with 18 of 161 patients (11.2%) assigned to discontinue treatment (4.1% per patient-year; average follow-up, 32.7 months); the rate ratio was 0.81 (95% CI, 0.42 to 1.56). All but one of the recurrences occurred after anticoagulant treatment was discontinued. Nineteen recurrences (57.6%) were episodes of pulmonary embolism, two of which were fatal. Three major bleeding episodes were observed during extended anticoagulation (1.8%). Among patients with idiopathic venous thromboembolism, 11 of 90 patients assigned to extended anticoagulation and 11 of 91 patients assigned to discontinue treatment experienced a recurrence (relative risk, 0.99 [CI, 0.45 to 2.16]). Conclusion: Patients with pulmonary embolism have a substantial risk for recurrence after discontinuation of oral anticoagulation, regardless of treatment duration. Physicians should try to identify patients who are at high risk for recurrent venous thromboembolism and are therefore potential candidates for indefinite oral anticoagulant therapy.

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1067/mob.2000.105941 Byline: Steven R. Goldstein Keywords: SERMs; selective estrogen receptor modulators; tamoxifen; raloxifene; breast cancer Abstract: Tamoxifen was approved for breast cancer prevention in October 1998. Thus, for the first time, we as gynecologists are being asked to prescribe this drug to healthy women. In the past each one of us has cared for women with breast cancer who have been treated with tamoxifen by oncologists or breast surgeons for the malignancy. Effects of tamoxifen on the uterus resulting in carcinomas, hyperplasia, and polyps are well known. Furthermore, tamoxifen has estrogenic properties in the venous system, increasing the incidence of deep vein thrombosis and pulmonary emboli. A new SERM (selective estrogen receptor modulator), raloxifene, has been approved for prevention and treatment of osteoporosis in postmenopausal women. It does not have stimulatory effects on the endometrium; however, it is estrogenic in the venous system. Preclinical data, as well as the breast cancer incidence reported in studies of the skeleton, seem to indicate that its effects in the breast are similar to those of tamoxifen. This article reviews tamoxifen and the new SERM, raloxifene, in an attempt to help gynecologists better understand each compound and what data are currently known, what we hope to learn from future studies, and what currently makes sense for clinical practice. (Am J Obstet Gynecol 2000;182:1121-6.) Author Affiliation: Department of Obstetrics and Gynecology, New York University School of Medicine New York, New York Article Note: (footnote) [star] Reprint requests: Steven R. Goldstein, MD, Department of Obstetrics and Gynecology, New York University School of Medicine, 530 First Ave, Suite 10N, New York, NY 10016.

Introduction: Pneumatic compression stocking (PCS) devices have been introduced to decrease the incidence of postoperative deep venous thrombosis (DVT). However, their role in the prophylaxis against pulmonary embolism (PE) remains [...]

Pharmacologic measures to prevent venous thromboembolism were first incorporated into the routine practice of general surgeons, urologists, and orthopedics in 1975, when the landmark International Multicenter Trial was published.[1] This [...]

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.amjsurg.2009.10.006 Byline: Joseph A. Caprini Keywords: Venous thromboembolism; Risk assessment; Prophylaxis; Postthrombotic syndrome; Deep vein thrombosis; Pulmonary embolism Abstract: Approximately 900,000 cases of deep vein thrombosis and pulmonary embolism occur annually in the United States, and one-third lead to the patient's death. A variety of surgical factors contribute to Virchow's triad of venous stasis, vascular injury, and hypercoagulability, including intraoperative venous distension and microvascular endothelial damage. Patients also may have individual risk factors such as a history of thromboembolism, cancer, advanced age, or a genetic trait linked to hypercoagulation. This article discusses recent trends in the development and validation of venous thromboembolism risk scores, including the results of a large validation study. Author Affiliation: University of Chicago, Pritzker School of Medicine, Chicago, IL, USA Article History: Received 23 July 2009; Revised 1 October 2009 Article Note: (footnote) Dr. Caprini is on the speakers' bureau for Covidien and sanofi-aventis; on the advisory board for ConvaTec, Covidien, Eisai, and sanofi-aventis; and a consultant for ConvaTec, Covidien, and sanofi-aventis.

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.amjsurg.2009.10.005 Byline: Marc A. Passman Keywords: Venous thromboembolism; Deep vein thrombosis; Pulmonary embolism; Prophylaxis; Quality care measure; Cost-effectiveness Abstract: Although considerable evidence describes optimal prevention and treatment of venous thromboembolism (VTE), a gap still exists in the implementation of these measures. With increasing recognition from quality accreditation organizations, VTE prevention recently has become a mandated health care quality measure. A broad effort to implement quality care measures in the health care system is under way, but the economic implications of this effort have yet to be realized. This article reviews the current status and future trends of quality care measures for VTE prevention and treatment and the potential economic implications of wider implementation of evidence-based guidelines. Author Affiliation: Section of Vascular Surgery and Endovascular Therapy, University of Alabama at Birmingham, Birmingham, AL, USA Article History: Received 23 July 2009; Revised 22 October 2009 Article Note: (footnote) No conflicts of interest exist.

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.amjsurg.2009.10.007 Byline: James E. Muntz (a)(b), Franklin A. Michota (c)(d) Keywords: Deep vein thrombosis; Venous thromboembolism; Pulmonary embolism; Prophylaxis; Treatment; Guidelines Abstract: Current evidence-based guidelines provide recommendations for prophylaxis and treatment of venous thromboembolism (VTE) in a variety of surgical patients. Author Affiliation: (a) Baylor College of Medicine, Houston, TX, USA (b) Memorial Hermann Sports Medicine Institute, University of Texas Health Center, Houston, TX, USA (c) Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA (d) Department of Hospital Medicine, Cleveland Clinic, Cleveland, OH, USA Article History: Received 23 July 2009; Revised 27 October 2009 Article Note: (footnote) Dr Muntz is a member of the advisory boards of Boehringer Ingelheim, Johnson & Johnson, and sanofi-aventis; a consultant for Bayer AG, Boehringer Ingelheim GmbH, sanofi-aventis, and Johnson & Johnson; and a member of the speakers' bureau of sanofi-aventis. Dr Michota is a member of the advisory boards of sanofi-aventis, Osaka Pharmaceuticals, Genentech Inc, and Ortho-McNeil/Johnson & Johnson and is a consultant and a member of the speakers' bureau of sanofi-aventis, Osaka Pharmaceuticals, and Genentech Inc.

The most common physical symptom of venous thromboembolism (VTE), a term that covers deep vein thrombosis (DVT) and pulmonary embolism (PE) is sudden swelling in one leg and mechanical options such as graduated compression stocking, intermittent pneumatic compression devices and venous foot pump. Different ways to learn to recognize who's at risk for this potentially fatal complication and how to reduce his risks are mentioned.

The patients having pulmonary embolism are at serious risk of death due to right ventricular failure. The successful fragmentation of thromboembolic material for pulmonary emboli is used to prevent these critical conditions.

Patients undergoing hip fracture surgery and receiving the selective Factor Xa inhibitor fondaparinux (Arixtra) for 4 weeks have a reduced risk of thromboembolic complications compared with those receiving the drug [...]

Fondaparinux sodium injection Organon/sanofi-synthelabo Factor Xa inhibitor for reducing risk of blood clots after orthopedic surgeries Fondaparinux has now been launched following its approval in December for prevention of deep [...]

EDITOR--The publication of the pulmonary embolism prevention (PEP) trial has created considerable interest in the medical and lay press about the optimal thromboprophylactic strategy to minimise the substantial morbidity and [...]

Vena Caval Filters for Pulmonary Embolism: Risks and Benefit ABSTRACT & COMMENTARY Synopsis: In a randomized, control trial, vena caval filter placement, in addition to anticoagulation, prevented pulmonary embolism in [...]

Venous thromboembolism (VTE)--deep vein thrombosis (DVT) and pulmonary embolism (PE)--remains a major cause of morbidity and mortality in the United States, resulting in an estimated 200,000 deaths each year. (1) [...]